Financial Performance
Sakar Healthcare reported an operating revenue of ₹72.97 crore for the first quarter of FY27, representing a 38.37% growth compared to the corresponding period in the previous fiscal year. The company's net profit stood at ₹10.28 crore, more than doubling from ₹4.67 crore in Q1 FY26. This growth was primarily fueled by the oncology division, which now contributes ₹33 crore to the quarterly revenue.
Operational efficiency also saw a significant boost, with EBITDA margins climbing to 29.12%. The management attributed this margin expansion to a superior product mix and the realization of operating leverage at its specialized manufacturing units.
Management Outlook
Management has provided a bullish outlook for the oncology segment, targeting a doubling of revenue in FY27 to approximately ₹180-200 crore. Looking further ahead, the company aims for oncology revenues of ₹280-300 crore by FY28. A core driver for this growth is the scaling of exports, which management expects to increase tenfold as international marketing authorizations come through.
The company plans to reach an EBITDA margin target of 35% or higher by integrating its in-house developed APIs. Currently, Sakar has 21 oncology APIs in its portfolio, with several already possessing or awaiting regulatory approvals in regulated markets.
Business and Segment Overview
Sakar Healthcare has successfully transformed into a specialized oncology player with a vertically integrated business model. Its Bawla facility is a cornerstone of this strategy, being EU-GMP approved and capable of handling oral solids, injectables, and APIs. The company currently manages 65 oncology product contracts and is exploring 50 additional international opportunities.
Tech-transfer projects have become an increasingly vital part of the business, with 33 ongoing projects involving major partners like Intas and Zydus. This shift from general formulations to high-barrier oncology products has significantly enhanced the company's competitive positioning and pricing power in both domestic and international markets.
What to Watch
- Scaling of oncology exports from the current base to a 10x target over the medium term
- Progress of 178 filed dossiers toward marketing authorization and commercial launch
- Impact of vertical API integration on EBITDA margins toward the 35% target
- Commercialization of 100+ registrations targeted by FY28 in regulated and emerging markets
- Utilization levels at the Bawla facility, which has a revenue potential of ₹800–1,000 crore
Management Commentary on Infrastructure
The Bawla oncology facility has been designed with significant growth potential and we believe it can support revenues of rupees 800 crores to rupees 1,000 crore at optimum utilization over the next four to five years without requiring any major incremental capital expenditure.
